Ximelagatran cost effectiveness for stroke prevention in atrial fibrillation

Society of Hospital Pharmacists of Australia
Publication Type:
Journal Article
Journal of Pharmacy Practice and Research, 2005, 35 (4), pp. 279 - 283
Issue Date:
Full metadata record
Files in This Item:
Filename Description Size
Thumbnail2010004375OK.pdf551.55 kB
Adobe PDF
Background: The benefit of warfarin for stroke prevention in non-valvular atrial fibrillation has been demonstrated in various clinical trials. Warfarin has a nan'ow therapeutic window and carries a significant risk ofbleeding. Ximelagatran is a new oral antithrombotic with predictable plasma concentrations and excellent bioavailability. Aim: To compare the costs and benefits of ximelagatran to that of warfarin and aspirin. Method: In a preliminary cost-effectiveness analysis, the costs and clinical consequences ofwarf31in, aspirin and ximelagatran were compared. The principal outcome was measured in the fonn of an incremental cost-effectiveness ratio. A decision analysis model was constructed to map the expected outcomes of three treatment alternatives. Sensitivity analysis tested the robustness of the data.
Please use this identifier to cite or link to this item: